Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-33911 EMEREN GROUP LTD (Exact name of Registrant as specified in its Charter) British Virgin Islands N/A (State or ...

Toronto, Ontario--(Newsfile Corp. - July 30, 2024) - SOL Global Investments Corp. (CSE: SOL) (OTC Pink: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company") today reported unaudited financial results for the second quarter ended May 31, 2024. The Company is also pleased to present a general operational update regarding its assets and investments. All figures in this press release are in Canadian dollars, unless otherwise indicated.Unaudited Results for the Six-Month Period Ended May 31, 2024For the six-month ...

Core Insights - Ocular Therapeutix is conducting a Phase 3 clinical trial named SOL-R to evaluate the safety and efficacy of AXPAXLI for treating wet age-related macular degeneration (wet AMD) [1][5] - The trial aims to compare AXPAXLI, administered every six months, to the current standard treatment of aflibercept, which is given every eight weeks [2][6] - The study will enroll approximately 825 patients, focusing on those who are treatment naïve or diagnosed with wet AMD within three months prior to enrollment [5][6] Group 1: Study Design and Objectives - SOL-R is a global, non-inferiority study designed to assess AXPAXLI against aflibercept, with a third arm for additional masking using a higher dose of aflibercept [2][5] - The primary endpoint is to demonstrate non-inferiority in mean best corrected visual acuity (BCVA) change from baseline between AXPAXLI and aflibercept at one year [6] - The trial incorporates a patient enrichment strategy, including multiple loading doses of aflibercept and monitoring to exclude patients with significant retinal fluid fluctuations [5][6] Group 2: Clinical Significance - The results from the SOL-R study are expected to provide valuable insights for the retina community regarding the potential of AXPAXLI in clinical practice [3] - The study is designed to align with real-world treatment experiences, potentially improving patient outcomes by allowing for a more convenient dosing schedule [3][5] - There is a significant need for durable treatments in wet AMD, as current therapies often lead to patient discontinuation and inadequate vision improvement [7] Group 3: Company Overview - Ocular Therapeutix is focused on developing innovative therapies for retinal diseases, with AXPAXLI being its lead product candidate [8] - The company utilizes its proprietary ELUTYX technology for AXPAXLI, which is a bioresorbable hydrogel implant incorporating axitinib, a multi-target tyrosine kinase inhibitor [4][8] - Ocular's pipeline also includes DEXTENZA, an FDA-approved product for ocular inflammation, and PAXTRAVA, which is in Phase 2 trials for glaucoma [9]

Emeren Group Ltd. (SOL) recently announced the sale of a ready-to-build (RTB) solar project portfolio of 42 megawatt peak (MWp) in Spain to CVE Espana. This divestment can be expected to boost SOL’s third-quarter 2024 revenues.This portfolio includes eight Greenfield plants, with sizes ranging from 5 to 6 megawatts (MW). One among these projects is already completed, while the rest are projected to be completed by Emeren in the third quarter of 2024.  The combined energy production from these eight projects ...

Transaction Details - Emeren Group successfully sold a 42 MWp RTB solar project portfolio in Spain to CVE España, a French IPP [1] - The portfolio consists of eight Greenfield projects developed since 2021, with sizes ranging from 5MW to 6MW [1] - One project has been closed, while the remaining seven will be completed in Q3 2024 [1] - The projects are located in Castilla-y-Leon, Comunidad Valenciana, and Andalucia [1] - The portfolio will generate 92,792.936 MWh/year, equivalent to the energy consumption of 28,360 households [1] - The projects will avoid approximately 20,093.73 tons of CO2 emissions annually [1] Strategic Impact - The transaction marks a significant milestone for Emeren Group's business in Spain, reinforcing its commitment to expanding solar and battery storage portfolios [2] - The Spanish PV market is described as competitive and promising, with a positive long-term outlook driven by policy support, technological advancements, and renewable energy emphasis [2] - CVE Group expects the transaction to triple its installed capacity in Spain to 65MWp by late 2025, aligning with its strategic goals of producing distributed solar energy and selling through PPAs [2] Company Profiles - Emeren Group is a global leader in renewable energy, specializing in solar project development, ownership, and operation, with a significant global Battery Energy Storage System (BESS) capacity [3] - The company focuses on the entire solar project lifecycle, leveraging local talent to ensure efficient and impactful sustainable energy solutions [3] - CVE Group is a French independent producer of renewable energies, operating in solar, biogas, and hydrogen across multiple countries [4] - The company aims to promote new business models based on direct energy sales, targeting industrial consumers, local authorities, businesses, and farmers [4] - CVE Group plans to reach a renewable installed capacity of 3.6 GWp by 2028 and is certified "B Corp" for high social and environmental standards [4]

STAMFORD, Conn., July 1, 2024 /PRNewswire/ -- Emeren Group Ltd ("Emeren" or the "Company") (www.emeren.com) (NYSE: SOL), a leading global solar project developer, owner, and operator, today announced a Development Service Agreement ("DSA") partnership for a state-of-the-art portfolio comprising five Battery Energy Storage Systems ("BESS") in Italy with PLT energia Srl ("PLT"), one of the largest independent Italian groups active in the energy sector from wind and photovoltaic sources. This transaction marks ...

Group 1: Core Insights - Solana (SOL) has experienced a significant price increase of nearly 800% over the past 12 months, turning a $1,000 investment into $9,000, despite currently being 26% off its 2024 peak [1] - Solana operates on a proof-of-stake (PoS) consensus algorithm, allowing it to process up to 50,000 transactions per second (TPS), vastly outperforming Ethereum's 14 TPS [2] - The viability of a cryptocurrency is linked to its real-world use cases, with Solana aiming to enhance accessibility through its web3-enabled smartphone, the Saga [3] Group 2: Use Cases and Potential - Solana Pay, launched in early 2022, connects consumers directly with merchants, enabling almost-free and instant transactions, which can increase merchant profits [4] - The introduction of NFTs as receipts could provide additional benefits to customers, enhancing the overall consumer experience [4] - Despite the potential in the payment sector, the smartphone market adoption rates for Solana's products are currently low, and consumer migration from established devices is uncertain [3]

Core Insights - Ocular Therapeutix is making significant progress in the clinical development of AXPAXLI for wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR) [1][2][3] - The company has announced plans for the SOL-R study to evaluate repeat doses of AXPAXLI in wet AMD, following positive results from the HELIOS NPDR study [1][4][5] Clinical Development Progress - As of June 7, 2024, 151 subjects have been enrolled in the pivotal SOL-1 study for AXPAXLI, with 60 active study sites [3][9] - The SOL-1 study aims to randomize 300 treatment-naïve patients, comparing AXPAXLI to aflibercept after initial loading doses of aflibercept [3][10] - The HELIOS NPDR study reported that 23.1% of patients in the AXPAXLI arm experienced a ≥2-step improvement in the diabetic retinopathy severity scale (DRSS) at 48 weeks, with no patients experiencing worsening [5][6] Future Studies and Strategy - The SOL-R study will evaluate AXPAXLI at six-month intervals compared to aflibercept dosed every eight weeks, with an expected enrollment of 825 patients [4][11] - The company is focusing on a retina-centric strategy built on strong clinical data, regulatory de-risking, and targeting expansive retinal vascular disease markets [2][8] Financial Position - Ocular Therapeutix has a cash runway projected into 2028, prioritizing resources for the clinical development of AXPAXLI and other key programs [7][15] Expert Commentary - Experts have noted the strong enrollment in the SOL-1 study, highlighting the lack of competing trials and the appeal of AXPAXLI's potential durability [8] - The SOL-R study is expected to provide valuable real-world data for physicians regarding the use of AXPAXLI if approved [8]

If Solana can convince investors it's the next Ethereum, it could skyrocket in value.In 2023, Solana (SOL -0.93%) was one of the top-performing major cryptocurrencies, up an eye-popping 900%. In 2024, Solana has continued to turn in a stellar performance. At its current price of $165, Solana is up more than 60% through the first five months of the year.The problem, however, is that Solana appears to be running into a wall right now. It is down nearly 20% since it hit an intra-year high of just over $200 in ...

Core Viewpoint - Solana is positioned for significant growth this summer, driven by mainstream consumer adoption and three key catalysts [1] Group 1: Spot Solana ETF - The potential launch of a spot Solana ETF could significantly increase its value, following the positive impacts seen with Bitcoin and Ethereum ETFs [2] - Solana ranks as the fifth-largest cryptocurrency with a market capitalization of $77 billion, making it a strong candidate for ETF consideration [2] Group 2: Meme Coin Mania - There is a surge in interest around meme coins, with Solana becoming the preferred blockchain for trading these assets, leading to increased activity on its network [3] - The introduction of free meme coins with the purchase of Solana's "crypto phone" has boosted sales, indicating the real-world impact of meme coin popularity [4] - The Phantom wallet app for Solana has surpassed downloads of major apps like Facebook, highlighting the growing interest in accessing meme coins [4] Group 3: PayPal Partnership - Solana's partnership with PayPal, which will see the launch of PayPal USD on its blockchain, is expected to enhance its appeal due to lower costs and higher speeds compared to Ethereum [5] - This collaboration could open new commerce and payment opportunities for Solana, potentially increasing its user base [5] Group 4: Competitive Landscape - June may be a critical month for Solana as new spot Ethereum ETFs are expected to launch, which could impact rival cryptocurrencies [6] - Despite potential challenges, Solana is gaining traction in mainstream adoption, with celebrities promoting its use for meme coin launches [6] - Solana's previous performance, with a nearly 900% increase in value last year, demonstrates its potential for future growth [6]